ST. LOUIS--(July 16, 2008) - GenoMed, Inc. (OTC Pink Sheets ticker symbol GMED), the Public Health Company™, announced today that its CEO’s views on health care reform are featured at ReformPlans.com, a popular website for healthcare reform ideas.
Here is the URL: http://www.reformplans.com/Features-and-Opinion/We-Need-to-Turn-Healthcare-on-Its-Head-David-Moskowitz-MD-for-Reform-Plans.html
Said Dr. David Moskowitz, GenoMed’s CEO, “The current national debate about healthcare completely misses the point. We’re told how great our healthcare is, that the argument is just about access. This is a lie which everybody involved in healthcare tells in one way or another. Seventy percent of healthcare dollars--currently $2.2 trillion a year in the US--is spent in the last year of a patient’s life. That means most of the revenues derive from the hospital and the nursing home, and are a complete waste of money. A healthcare system which kept people out of the hospital and the nursing home would be far cheaper and far more desirable from the taxpayers’ point of view. But there are enormous financial interests--$2.2 trillion a year--preventing this from happening. The entire healthcare system is against it.”
Dr. Moskowitz continued, “Nobody involved in healthcare, starting with academic medical centers and non-profit fund-raisers, wants to kill the golden goose. Nobody wants to defeat disease, although they’re happy to study it to death. In effect, there’s a conspiracy to preserve the status quo, and continue to let disease win.”
Dr. Moskowitz ended by saying, “The status quo is preserved in a host of different ways. My personal favorite is the conspiracy of silence. Fifteen years ago I found a master disease gene. It alone can probably save 5% of healthcare costs, and extend life by 5-10 years. In the 1930s, this would have been big news, like penicillin. For the past decade, though, it’s been a well-kept secret, despite the Information Age we’re supposed to live in.”
About GenoMed
GenoMed, Inc. is a Next Generation Disease Management (DM) company that uses genomics, the knowledge of which genes cause disease, to improve patient outcomes. It is the only DM company that can reverse early kidney failure due to diabetes or high blood pressure. Medicare pays $25 billion a year for kidney transplantation and dialysis; GenoMed can prevent 90% of kidney failure. To illustrate what GenoMed and taxpayers are up against, since 2004, Medicare has had no interest in GenoMed’s ability to eliminate 90% of their dialysis budget. To join GenoMed’s Clinical Outcomes Improvement Program, or COIP®, contact Dr. Moskowitz at dwmoskowitz@genomed.com.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company’s) treatments and business model. The words or phrases “would be,” “ought to,” “potential,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether patients with crush injury respond to this treatment approach, especially if they are rescued after a long time; (b) whether we will have sufficient financing to conduct our research and development; (c) how competition from existing or new competitors will impact our business, and (d) our research and development being subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contact:
David Moskowitz MD
CEO, GenoMed, Inc.
tel. 314-983-9938
dwmoskowitz@genomed.com
